Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 6/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31022070 | 0.78 | ASIC3 (0.74) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL587208 | 0.77 | ASIC3 (0.60) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL27721456 | 0.76 | ASIC3 (0.59) | ASIC3DRD2DRD3CD274PNMT | |
| Hydrochloric Acid SCHEMBL588201 | 0.75 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL27700750 | 0.75 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274PNMT | |
| Hydrochloric Acid SCHEMBL587643 | 0.74 | ASIC3 (0.56) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL2675790 | 0.73 | ASIC3 (0.67) | ASIC3DRD2DRD3PNMT | |
| SCHEMBL27928333 | 0.72 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274TLR9 | |
| SCHEMBL1011047 | 0.72 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL1010614 | 0.72 | ASIC3 (0.61) | ASIC3DRD2DRD3CD274PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700604-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ASIC3 3925/4885DRD2 2638/4885DRD3 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.